Each year, American Society of Clinical Oncology (ASCO) Annual Meeting brings together the global oncology community to present and deliberate over some of the most important new research shaping cancer care. The 2026 meeting was held under the theme “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide”, a call to think about how discoveries move from the laboratory into the clinic, from clinical trials into real-world care, and ultimately to cancer patients across different healthcare settings.
This theme proved particularly fitting. ASCO 2026 delivered important new data across tumor types and therapeutic modalities, from targeted therapies and immunotherapy to antibody-drug conjugates (ADCs), bispecific antibodies and increasingly sophisticated diagnostic tools. But viewed together, many of the meeting’s most interesting developments pointed to a broader shift.
The next phase of progress in oncology will depend as much on what we do with the advances we have already made as on what we discover next. As the therapeutic and diagnostic toolkit expands, the questions are becoming more nuanced: Which patients should receive treatment, and which can safely receive less? When should a therapy be introduced? Where does it belong in an increasingly complex treatment pathway? What should it be combined with? And how do we ensure that promising results translate into meaningful benefit in clinical practice?
In other words, the opportunity now is not only to discover new possibilities, but to build intelligently on the biological insights, therapeutic tools and clinical experience oncology has already gained.
From Proving Efficacy to Defining Value
As the number and sophistication of available cancer therapies continues to grow, demonstrating efficacy remains essential, but so too does defining where a therapy can deliver the greatest value within an increasingly complex treatment landscape.
Several of the major studies presented at ASCO 2026 illustrated just how differently that question can be answered. In early breast cancer, the OPTIMA trial showed how genomic profiling could identify a large group of patients who could safely avoid chemotherapy.[1] In RET fusion-positive non-small cell lung cancer (NSCLC), LIBRETTO-432 demonstrated the potential value of moving targeted therapy into the adjuvant setting, after surgery or radiotherapy.[2] And in high-risk localized prostate cancer, PROTEUS explored treatment intensification around surgery, adding systemic therapy both before and after prostatectomy.[3]
The same question is emerging as therapeutic options multiply within individual disease areas. In multiple myeloma, for example, results with teclistamab raised the question of whether highly active T-cell-redirecting therapies should be used earlier rather than reserved for later lines of treatment, while also highlighting the importance of selecting between modalities according to patient fitness, disease characteristics, toxicity, access and practical considerations.[4]
Taken together, these studies show that progress can mean very different things: intensifying treatment, moving it earlier, selecting a different modality or safely administering less. Patient selection, treatment setting and sequencing are therefore becoming increasingly important development questions in their own right. They influence how trials are designed, which comparators are chosen, and, ultimately, where a therapy belongs within an evolving standard of care.
Building on Complementary Biology
ASCO 2026 also highlighted how progress is increasingly coming from combining therapeutic approaches with complementary mechanisms of action.
In advanced squamous NSCLC, the phase III HARMONi-6 study explored a combination strategy that targeted both immune checkpoint signaling and the tumor microenvironment (TME) with ivonescimab, a bispecific antibody targeting both PD-1 and VEGF. While PD-1 blockade is designed to restore antitumor immune activity, while blocking VEGF inhibits tumor angiogenesis and may help normalize the abnormal vasculature and immunosuppressive conditions within the TME.
In over 500 patients treated in China, ivonescimab plus chemotherapy significantly improved overall survival compared with PD-1 inhibitor tislelizumab plus chemotherapy, with median survival of 27.9 versus 23.7 months and a 34% reduction in the risk of death, with the benefit observed across PD-L1 subgroups. While validation in broader global populations is still needed, the findings provide compelling clinical evidence for combining immune checkpoint inhibition with VEGF-mediated modulation of tumor angiogenesis and the TME, alongside chemotherapy.[5]
A different example came from the phase III OptiTROP-Lung05 study, which combined the TROP2-directed ADC sacituzumab tirumotecan with pembrolizumab in previously untreated, PD-1 positive advanced NSCLC. In this study, the rationale was to combine the targeted delivery of a cytotoxic payload with immune checkpoint inhibition. Among 413 patients, the combination reduced the risk of disease progression or death by 65% compared with pembrolizumab alone; the objective response rate was 70.2% versus 42.0%.[6] The improvement came with greater toxicity, however, with grade 3 or higher treatment-emergent adverse events reported in 55.3% of patients receiving the combination compared with 31.4% receiving pembrolizumab alone.
HARMONi-6 and OptiTROP-Lung05 illustrate why combination development is becoming more biologically deliberate. In this context, the question is increasingly whether targeting complementary mechanisms can produce a clinically meaningful improvement and whether that additional benefit justifies the additional toxicity and treatment burden. As the therapeutic toolkit expands, the strength of the biological rationale behind a combination, alongside careful patient selection and trial design, will become increasingly important in determining which combinations ultimately change practice.
From Evidence to Implementation
Translation doesn’t end when a clinical trial produces a positive result. ASCO 2026 highlighted the challenges of turning evidence into care that can be delivered consistently in everyday clinical practice.
Geriatric oncology provided a particularly clear example. Randomized trials have already established that geriatric assessment can reduce treatment toxicity, improve patient-centered care and support treatment decisions in older adults with cancer. Yet implementation remains uneven, constrained by limited access to geriatric specialists, staffing pressures, time and the complexity of integrating additional assessments into already demanding clinical workflows. This challenge has relevance far beyond geriatric oncology itself, as aging populations worldwide mean that a growing proportion of people diagnosed with cancer will also face the vulnerabilities and complexities associated with older age. At ASCO 2026, attention therefore shifted toward how geriatric assessment and supportive care could be integrated more consistently and at greater scale into routine oncology practice.[7]
Studies explored nurse-led multidisciplinary models, telehealth-enabled supportive care and community-based approaches designed to integrate geriatric assessment into routine oncology practice. Artificial intelligence was also investigated as a potential means of extending limited clinical capacity. The GRACE study evaluated a conversational AI platform designed to conduct elements of geriatric assessment and identify vulnerabilities that could influence treatment and supportive care.[7] While larger studies are still needed to establish its clinical impact, the work illustrates an increasingly important translational question for AI in oncology: can AI be validated and integrated into clinical workflows in a way that improves care without creating additional burden for healthcare professionals?
This is an important extension of the precision oncology question. Better treatments, diagnostics and decision-support tools can only improve outcomes if they can be translated into workable models of care. As oncology becomes more sophisticated, implementation itself is therefore becoming an increasingly important part of the scientific challenge.
Looking Beyond the Tumor
Beyond the TME, ASCO 2026 also highlighted the importance of the wider biological context in which cancer develops and responds to therapy, including systemic factors such as metabolism, inflammation, nutrition, and the patient’s broader physiology.
One study involving more than 12,000 patients examined the progression of seven obesity-associated cancers in people taking GLP-1 receptor agonists compared with other glucose-lowering therapies. GLP-1 receptor agonist use was associated with lower risk of progression to metastatic disease in lung, breast, colorectal and liver cancers.[8] The findings are observational and cannot establish that GLP-1 treatment itself caused the difference, but they raise important questions about the relationship between metabolic health and cancer biology. Researchers are now investigating whether potential effects may involve inflammation, immune function, tumor metabolism or direct interactions with cancer and surrounding cells.
Other studies presented at the meeting similarly explored how factors outside conventional tumor-directed treatment, from weight and nutrition to metabolic interventions, might influence treatment response, symptoms, and quality of life.[9-11] Collectively, this work reinforces an increasingly important principle: cancer does not develop or respond to therapy in biological isolation. Understanding the patient’s broader physiological state, and how it interacts with both the tumor and its microenvironment, may open additional opportunities to improve treatment strategies and patient outcomes.
When A New Therapeutic Door Opens
In some settings, defining value begins with creating a meaningful new option where few effective treatments exist.
In previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), the phase III RASolute 302 trial showed that daraxonrasib, an oral RAS(ON) multi-selective inhibitor, nearly doubled median overall survival compared with chemotherapy, from 6.7 to 13.2 months. The objective response rate also increased from 11.8% to approximately 33%. Presented at the ASCO Plenary Session, the results drew a rare 42-second standing ovation and were described as the most significant advance in systemic treatment for pancreatic cancer in more than a decade.[12] But they also mark a beginning rather than an endpoint: resistance to daxaronasib is already emerging as a key research challenge, alongside questions around rational combination strategies and whether the therapy could deliver benefit in earlier treatment settings.[12]
In many ways, daxaronasib brings the broader ASCO 2026 narrative into focus. The breakthrough itself is only the first step in translation. The next phase is to define whether the therapy delivers its greatest value: which patients are most likely to benefit, where it should sit in the treatment pathway, whether moving it into earlier disease could extend its impact, how emerging resistance might be overcome, and which combinations are supported by the strongest biological rationale. These are the same questions that ran through the meeting more broadly, from treatment selection and sequencing to rational combinations and implementation in clinical practice.
A new therapeutic door has opened in pancreatic cancer. The challenge now is to determine how best to use what lies beyond it.
References:
1. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/258169/abstract
2. Goldman JW, et al. Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion-positive NSCLC: primary results of the phase 3 LIBRETTO-432 trial. J Clin Oncol. 2026;44(17_suppl):LBA3. doi:10.1200/JCO.2026.44.17_suppl.LBA3
3. Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): final analysis of the PROTEUS phase 3 study. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/260407/abstract
4. Helwick C. ASCO 2026: multiple myeloma studies highlight advances across the field. The ASCO Post. July 25, 2026. Accessed September 8, 2026. https://ascopost.com/issues/july-25-2026/multiple-myeloma-studies-highlight-advances-across-the-field/
5. Ivonescimab may improve overall survival in patients with advanced squamous non-small cell lung cancer. News release. American Society of Clinical Oncology; May 31, 2026. Accessed September 8, 2026. https://www.asco.org/about-asco/press-center/ivonescimab-may-improve-survival-squamous-nsclc
6. Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC): results from the randomized phase 3 OptiTROP-Lung05 study. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/259330
7. Zhi I. The 2026 ASCO Annual Meeting geriatric oncology update: the next challenge is implementation. The ASCO Post. September 3, 2026. Accessed September 8, 2026. https://ascopost.com/news/september-2026/the-2026-asco-annual-meeting-geriatric-oncology-update-the-next-challenge-is-implementation/
8. GLP-1s may reduce metastatic progression of certain obesity-related cancers. News release. American Society of Clinical Oncology; May 21, 2026. Accessed September 8, 2026. https://www.asco.org/about-asco/press-center/glp-may-reduce-metastatic-progression
9. Impact of a whole-food plant-based diet (WFPBD) on weight and metabo-inflammation in men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): a multi-center randomized control trial. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/260795
10. The effects of Mediterranean diet, physical activity, and vitamin D on breast cancer recurrence and cardiometabolic health: a multicenter randomized trial. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/263791
11. Impact of protein-energy malnutrition on outcomes of metastatic triple-negative breast cancer patients receiving chemotherapy: a real-world analysis. Presented at: 2026 ASCO Annual Meeting; May 29–June 2, 2026; Chicago, IL. Accessed September 8, 2026. https://www.asco.org/abstracts-presentations/261289
12. Prakash A, Lou E. Daraxonrasib in KRAS-mutant pancreatic cancer: a first step in shifting the paradigm of treatment. The ASCO Post. June 10, 2026. Accessed September 8, 2026. https://ascopost.com/issues/june-10-2026/daraxonrasib-in-kras-mutant-pancreatic-cancer-a-first-step-in-shifting-the-paradigm-of-treatment/